Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21117369 | 0.89 | PDE4B (0.61) | PDE4BHSD17B10GRIN1GRIN2B | |
| SCHEMBL21087117 | 0.88 | PDE4B (0.64) | PDE4BHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL21117546 | 0.88 | PDE4B (0.62) | PDE4BHSD17B10GRIN1GRIN2B | |
| SCHEMBL21117374 | 0.88 | PDE4B (0.64) | PDE4BHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL21117550 | 0.86 | PDE4B (0.61) | PDE4BHSD17B10GRIN1GRIN2B | |
| SCHEMBL21117394 | 0.85 | PDE4B (0.68) | PDE4BHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL21117398 | 0.85 | PDE4B (0.54) | PDE4BGRIN1GRIN2B | |
| SCHEMBL21117373 | 0.84 | PDE4B (0.51) | PDE4BHSD17B10KDM4EALDH1A1TP53 | |
| SCHEMBL21117315 | 0.84 | PDE4B (0.60) | PDE4BHSD17B10KDM4EALDH1A1 | |
| SCHEMBL21113764 | 0.83 | GRIN1 (0.52) | PDE4BHSD17B10KDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662189-B2 | PDE4 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3502111-A1 | PDE4 INHIBITOR | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-26 | — | — | EP | disclosed |
| US-20190177318-A1 | PDE4 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177318-A1 | PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885HSD17B10 177/4885KDM4E 711/4885 |
| US-10662189-B2 | PDE4 inhibitor | PDE4A, PDE12, PDE4B | PDE4B 3/4885HSD17B10 177/4885KDM4E 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.